Upload Avatar (500 x 500)
Nan Nan Lu
Mayo Clinic College of Medicine
University of Science and Technology of China
Anhui
Language: Chinese, English
Nano-Drug Delivery
Tumor Microenvironment
Anti-Tumor Mechanism
Breast Tumors
Clinical Research
Vaccine Therapy
Targeted Drug Monitoring
Ai Analysis
Malignant Tumors
Translational Research
Areas of Focus
- Construction and anti-tumor mechanism of malignant tumor microenvironment-responsive nano-drug delivery systems
- Observational and translational research on breast tumors
- Clinical application of new in-situ vaccine therapy technologies for advanced breast tumors
- Application of anti-tumor small molecule targeted drug concentration monitoring in clinical treatment
- Role of AI big data analysis in clinical and basic research of malignant tumors
Work Experience
- 2024.06-present - University of Science and Technology of China, First Affiliated Hospital - Director of Breast Tumor Internal Medicine Subspecialty
- 2024.01-present - University of Science and Technology of China, First Affiliated Hospital - Chief Physician
- 2019.09-2023.09 - University of Science and Technology of China - Postdoctoral Researcher in Biology
- 2019.01-2023.12 - University of Science and Technology of China, First Affiliated Hospital - Associate Chief Physician
- 2018.03-2018.06 - Mary Washington Hospital, USA - Visiting Scholar
- 2016.01-2018.12 - University of Science and Technology of China, First Affiliated Hospital - Attending Physician
- 2012.07-2015.12 - Anhui Provincial Hospital - Physician
Academic Background & Achievements
- PhD in Oncology: University of Science and Technology of China
- Postdoctoral Research: University of Science and Technology of China
- Visiting Scholar: Mary Washington Hospital, USA
- Published over 30 academic papers in renowned journals
Publications
- Development of a Multiparametric Model for Predicting the Response to Neoadjuvant Chemotherapy in Breast Cancer, F. Qian, Y. Mao, J. Dong, F. Xie, X. Fang, Q. Zhang, P. Xia, X. Han*, N. Lu*, 2024
- Immune Microenvironment and Clinical Feature Analyses Based on a Prognostic Model in Lymph Node-positive Breast Cancer, N. Lu#, C. Fu#, L. Zhang, Y. You, X. Li, Q. Zhang, P. Wang*, X. Han*, 2023
- Acid-Responsive Endosomolytic Polymeric Nanoparticles with Amplification of Intracellular Oxidative Stress for Prodrug Delivery and Activation, N. Lu, L. Xi, Z. Zha, Y. Wang, X. Han*, Z. Ge*, 2021
- Predicting Pathologic Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer using Multiparametric MRI, N. Lu, J. Dong, X. Fang, L. Wang, W. Jia, Q. Zhou, L. Wang, J. Wei, Y. Pan, X. Han*, 2021
- Length effect of stimuli-responsive block copolymer prodrug filomicelles on drug delivery efficiency, W. Ke#, N. Lu#, A.A.-W.M.M. Japir, Q. Zhou, L. Xi, Y. Wang, D. Dutta, M. Zhou, Y. Pan, Z. Ge*, 2020
- Hypoxia-Responsive Polyprodrug Nanocarriers for Near Infrared Light-Boosted Photodynamic-Chemotherapy, D. Dutta, Q. Zhou, J. F. Mukerabigwi, N. Lu* (共同通讯作者), Z. Ge*, 2021
- Cisplatin Resistance Reversal of Lung Cancers by Tumor Acidity-Activable Vesicular Nanoreactors via Tumor Oxidative Stress Amplification, J.F. Mukerabigwi, Y. Han, N. Lu* (共同通讯作者), W. Ke, Y. Wang, Q. Zhou, F. Mohammed, A. Ibrahim, B. Zheng*, Z. Ge*, 2021
- Protein-Delivering Nanocomplexes with Fenton Reaction-Triggered Cargo Release to Boost Cancer Immunotherapy, X. Li, Q. Zhou, A.A.-W.M.M. Japir, D. Dutta, N. Lu, Z. Ge*, 2022
- Hypoxia-responsive block copolymer polyprodrugs for complementary photodynamic-chemotherapy, Q. Zhou, F. Mohammed, Y. Wang, J. Wang, N. Lu, J. Li*, Z. Ge*, 2021
Awards
- Anhui Province First Health and Wellness 'Key Talent' (2022): Provincial Level
- Third 'Outstanding Young and Middle-aged Talent' (2023): Hospital Level
- Best Contribution Individual Award (2022): Hospital Level
- Excellent Doctoral Award (2019): Hospital Level
- Single Outstanding Paper Award (2018): Hospital Level
